Skip to main content
SpringerLink
Log in

Transarterial Therapies for Hepatocellular Carcinoma

  • Chapter
  • First Online:
Multidisciplinary Treatment of Hepatocellular Carcinoma

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 190))

Abstract

Transarterial therapies for hepatocellular carcinoma are considered palliative and should be offered to patients with intermediate stage multinodular disease without extra-hepatic metastases and sufficient liver reserve. They mainly include transarterial chemoembolisation and transarterial embolisation. While transarterial therapy is now a validated treatment for unresectable HCC, there is still a lack of conclusive evidence as to which type and schedule is the optimal procedure. This is mainly due to the lack of standardisation. Combining local therapies or intra-arterial therapies with systemic targeted therapies might prove more effective strategies in the future. In the present article, we review transarterial therapies and critically comment on their indications, complications and outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 229.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576

    Article  PubMed  CAS  Google Scholar 

  2. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236

    Article  PubMed  Google Scholar 

  3. Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Pinelopi M, Arvaniti V, Burroughs AK (2008) Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2:761–784

    Article  PubMed  CAS  Google Scholar 

  4. Llovet JM, Fuster J, Bruix J (2004) The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10:S115–S120

    Article  PubMed  Google Scholar 

  5. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS (2005) Prognosis of hepatocellular carcinoma: comparison of seven staging systems in an American cohort. Hepatology 41:707–716

    Article  PubMed  Google Scholar 

  6. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC (2009) Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20:S425–S434

    Article  PubMed  Google Scholar 

  7. Maeda S, Fujiyama S, Tanaka M, Ashihara H, Hirata R, Tomita K (2002) Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 23:202–210

    Article  PubMed  CAS  Google Scholar 

  8. Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T, Sato K, Yamamoto S, Hinotsu S, Sato T (2009) Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 51:1030–1036

    Article  PubMed  CAS  Google Scholar 

  9. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25

    Article  PubMed  Google Scholar 

  10. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442

    Article  PubMed  CAS  Google Scholar 

  11. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  PubMed  CAS  Google Scholar 

  12. Piscaglia F, Bolondi L (2010) The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 42(Suppl 3):S258–S263

    Article  PubMed  Google Scholar 

  13. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739

    Article  PubMed  Google Scholar 

  14. Giannini EG, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del PP, Benvegnu L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F (2010) Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 31:493–501

    Article  PubMed  CAS  Google Scholar 

  15. Bhattacharya S, Novell JR, Winslet MC, Hobbs KE (1994) Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 81:1563–1571

    Article  PubMed  CAS  Google Scholar 

  16. Dodds HM, Walpole ET, Rivory LP, Strong RW, Pond SM (1996) Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma. Ther Drug Monit 18:537–543

    Article  PubMed  CAS  Google Scholar 

  17. Johnson PJ, Kalayci C, Dobbs N, Raby N, Metivier EM, Summers L, Harper P, Williams R (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13:120–127

    Article  PubMed  CAS  Google Scholar 

  18. Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, Fujita M, Ishiguro S (1989) Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 97:965–971

    PubMed  CAS  Google Scholar 

  19. Lu W, Li Y, He X, Chen Y (2003) Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology 50:2079–2083

    PubMed  Google Scholar 

  20. Coldwell DM, Stokes KR, Yakes WF (1994) Embolotherapy: agents, clinical applications, and techniques. Radiographics 14:623–643

    PubMed  CAS  Google Scholar 

  21. Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, Crippin JS (2005) Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16:1661-1666

    Google Scholar 

  22. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108

    Article  PubMed  CAS  Google Scholar 

  23. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montana X, Llovet JM, Bruix J (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481

    Article  PubMed  CAS  Google Scholar 

  24. Kettenbach J, Stadler A, Katzler IV, Schernthaner R, Blum M, Lammer J, Rand T (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468–476

    Article  PubMed  Google Scholar 

  25. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52

    Article  PubMed  Google Scholar 

  26. Tsochatzis EA, Germani G, Burroughs AK (2010) Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 37:89–93

    Article  PubMed  CAS  Google Scholar 

  27. Tsochatzis E, Meyer T, Marelli L, Burroughs A (2010b) Which transarterial therapy is best for hepatocellular carcinoma? – The evidence to date. J Hepatol 53:588

    Google Scholar 

  28. Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z (2006) Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 41:516–521

    Article  PubMed  Google Scholar 

  29. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103:914–921

    Article  PubMed  Google Scholar 

  30. Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, Kulik LM, Szolc-Kowalska B, Woloschak GE, Yang GY, Salem R, Larson AC, Omary RA (2008) Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 19:1483–1489

    Article  PubMed  Google Scholar 

  31. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, Emmanouil E, Rizos S, Kelekis D (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541–551

    Article  PubMed  Google Scholar 

  32. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74:2449–2453

    Article  PubMed  CAS  Google Scholar 

  33. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma–a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 31(Suppl):S1–S6

    Article  PubMed  Google Scholar 

  34. Meyer T, Roughton M, Yu D, Davies N, Williams E, Pereira P, Hochhauser J, O’Beirne J, Patch D, Burroughs A (2010) A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC). J. J Clin Oncol 28(suppl 1):15s

    Google Scholar 

  35. Burroughs A, Hochhauser D, Meyer T (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5:409–418

    Article  PubMed  Google Scholar 

  36. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC (2001) Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12:321–326

    Article  PubMed  CAS  Google Scholar 

  37. Helmberger T, Dogan S, Straub G, Schrader A, Jungst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann RT, Lohe F, Graeb C, Rau HG, Schauer R, Jauch KW, Caselmann WH, Goke B, Jungst D (2007) Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 75:104–112

    Article  PubMed  Google Scholar 

  38. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G (2006) Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 16:661–669

    Article  PubMed  Google Scholar 

  39. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP (2005) Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 11:6104–6109

    PubMed  Google Scholar 

  40. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK (2010) Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 52:380–388

    Article  PubMed  CAS  Google Scholar 

  41. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  PubMed  CAS  Google Scholar 

  42. Fatourou EM, Koskinas JS (2009) Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Rev Anticancer Ther 9:1499–1510

    Article  PubMed  CAS  Google Scholar 

  43. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S (2001) Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48:87–96

    Article  Google Scholar 

  44. Reyes D, Azad N, Kamel I (2009) Phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma: interim safety and efficacy analysis. American Association of the Study of Liver Diseases, Boston, MA USA, November 2009 Late breaker abstract 9

    Google Scholar 

  45. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699

    Article  PubMed  CAS  Google Scholar 

  46. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK (2007) Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 33:437–447

    Article  PubMed  CAS  Google Scholar 

  47. Tsochatzis E, Garcovich M, Marelli L, Fede G, Germani G, Manousou P, Arvaniti V, Georgiadis D, Burroughs A (2010) Transarterial chemoembolization as neo-adjuvant therapy pre-transplantation in patients with hepatocellular carcinoma. Hepatology 52(Suppl 1):858A–859A

    Google Scholar 

  48. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Yu D, Meyer T, Patch DW, Burroughs AK (2006) Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 32:594–606

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Royal Free Sheila Sherlock Liver Centre and Division of Surgery, Royal Free Hospital and UCL, , Pond Street, Hampstead, London, NW3 2QG, UK

    Emmanuel A. Tsochatzis, Evangelia M. Fatourou, Christos K. Triantos & Andrew K. Burroughs

Authors
  1. Emmanuel A. Tsochatzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evangelia M. Fatourou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christos K. Triantos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew K. Burroughs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew K. Burroughs .

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, Dept. Surgical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Jean-Nicolas Vauthey

  2. , Dept. of Surgical Oncology, MD Anderson Cancer Center, Holcombe Boulevard, Unit 444 1515, Houston, 77030, USA

    Antoine Brouquet

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Tsochatzis, E.A., Fatourou, E.M., Triantos, C.K., Burroughs, A.K. (2013). Transarterial Therapies for Hepatocellular Carcinoma. In: Vauthey, JN., Brouquet, A. (eds) Multidisciplinary Treatment of Hepatocellular Carcinoma. Recent Results in Cancer Research, vol 190. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16037-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-16037-0_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-16036-3

  • Online ISBN: 978-3-642-16037-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation